Multi-site analytical evaluation of the abbott architect tacrolimus assay

Therapeutic Drug Monitoring

Volumn 31, Issue 2, 2009, Pages 198-204

  Wallemacq, Pierre ^a   Goffinet, Jean Sebastien ^a   O'Morchoe, Susan ^b   Rosiere, Thomas ^b   Maine, Gregory T ^b   Labalette, Myriam ^c   Aimo, Giuseppe ^d   Dickson, Diana ^e   Schmidt, Ed ^e   Schwinzer, Reinhard ^f   Schmid, Rainer W ^g  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b ABBOTT DIAGNOSTICS   (United States)

^c Hospital Universitario de Lille   (France)

^d MOLINETTE HOSPITAL   (Italy)

^e Fujirebio Diagnostics ^*  (Sweden)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

FK 506; Immunoassay; LC MSMS; Method evaluation; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

ACRIDINE; BILIRUBIN; CHOLESTEROL; METHANOL; TACROLIMUS; TRIACYLGLYCEROL; URIC ACID; ZINC SULFATE; IMMUNOSUPPRESSIVE AGENT;

ANALYTICAL ERROR; ANALYZER; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; EVALUATION RESEARCH; HUMAN; IMMUNOASSAY; LABORATORY TEST; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MASS SPECTROMETRY; MICROPARTICLE ENZYME IMMUNOASSAY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; BLOOD; CLINICAL TRIAL; MULTICENTER STUDY; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; REPRODUCIBILITY OF RESULTS; TACROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 65349168820     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819c6a37     Document Type: Article

References (20)

1. Wallemacq P, Reding R. FK506 (Tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical and analytical aspects. Clin Chem. 1993;39:2219-2228.
2. Chen TS, Arison BH, Wicker LS, et al. Microbial transformation of immunosuppressive compounds I. Desmethylation of FK506 and immunomycin (FR 900520) by Actinoplanes sp. ATCC 53771. J Antibiotics. 1992;45:118-123.
3. Chen TS, Arison BH, Wicker LS, et al. Microbial transformation of immunosuppressive compounds II. Specific desmethylation of 13-methoxy group of FK506 and FR 900520 by an unidentified Actinomycete ATCC 53828. J Antibiotics. 1992;45:577-580.
4. Perotti BYT, Okudaira N, Prueksaritanont T, et al. FK506 metabolism in male and female rat liver microsomes. Drug Metab Dispos. 1994;22:85-89.
5. Westgard JO. Basic Method Validation, 3rd ed. Madison, WI: Westgard QC, Inc; 2008, 168-174.
6. Clinical and Laboratory Standards Institute. Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. CLSI document EP7-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
7. National Committee for Clinical Laboratory Standards. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline - Second Edition. NCCLS document EP5-A2. Wayne, PA: NCCLS, 2004.
8. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem. 1983;21:709-720.
9. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
10. Radomski KM, Bush BA, Ensom MHH. Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugs. Ann Pharmacother. 1998;32:170-175.
11. Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation. 2007;83:411-416.
12. Ekberg H, Tedesco-Silva H, Demirbas A, et al. The ELITE-Symphony study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562-2575.
13. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
14. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood. Clin Chem. 2002;48:955-958.
15. Napoli K. Organic solvents compromise performance of internal standard (ascomycin) in proficiency testing of mass spectrometry-based assays for tacrolimus. Clin Chem. 2006;52:765-766.
16. Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin Biochem. 2005;38:328-334.
17. Vogeser M. Instrument specific matrix effects of calibration materials in the LC-MS/MS analysis of tacrolimus. Clin Chem. 2008;54:1406-1408.
18. Murthy JN, Davis DL, Yatscoff RW, et al. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem. 1998;31:613-617.
19. Iwasaki K, Shiraga T, Matsuda H, et al. Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos. 1995;23:26-34.
20. Goffinet JS, Mullier F, Capron A, et al. Evaluation of three immunoassays to quantify tacrolimus: impact of hematocrit (Abstract). Ther Drug Monit. 2007;29:508.